Advertisement
UK markets close in 2 hours 45 minutes
  • FTSE 100

    8,100.25
    +59.87 (+0.74%)
     
  • FTSE 250

    19,735.40
    +16.03 (+0.08%)
     
  • AIM

    755.74
    +1.05 (+0.14%)
     
  • GBP/EUR

    1.1664
    +0.0019 (+0.16%)
     
  • GBP/USD

    1.2478
    +0.0016 (+0.13%)
     
  • Bitcoin GBP

    51,055.36
    -2,282.28 (-4.28%)
     
  • CMC Crypto 200

    1,361.83
    -20.74 (-1.50%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CRUDE OIL

    83.20
    +0.39 (+0.47%)
     
  • GOLD FUTURES

    2,338.10
    -0.30 (-0.01%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • DAX

    17,997.76
    -90.94 (-0.50%)
     
  • CAC 40

    8,023.67
    -68.19 (-0.84%)
     

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc

BOSTON and LONDON, June 06, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced that Saurabh Saha, MD, PhD, Chief Executive Officer and Gregory Weinhoff, MD, Chief Financial Officer, will participate in the following investor conferences:

Event: Jefferies Healthcare Conference
Date: Thursday, June 9, 2022
Fireside Chat Webcast Time: 4:30 PM ET

Event: Goldman Sachs 43rd Annual Global Healthcare Conference
Date: Wednesday, June 15, 2022
Fireside Chat Webcast Time: 8:00 AM PT/ 11:00 AM ET

ADVERTISEMENT

Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at Events & Presentations | Centessa Pharmaceuticals.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc (“Centessa”) is a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. We are led by a management team with extensive R&D experience, providing direct guidance to our program teams to rapidly advance our candidates from research through all stages of development. For more information, visit www.centessa.com, which does not form part of this release.

Contact:

Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com